NG-641

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameNG-641
Drug Alias NameEnAd-FAP-BiTEEnAd-FAP-TacNG-641NG-aFAP
ClassificationBiologics > Oncolytic virusCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vectorBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody +[4] 
Mechanisms of ActionAnti-CD3Anti-Prolyl endopeptidase FAPInterferon alpha-2 modulators +[5] 
TargetsT cell surface glycoprotein CD3Prolyl endopeptidase FAPInterferon alpha-2 +[5] 
Therapy Area/IndicationsNeoplasm MetastasisSquamous Cell Carcinoma of Head and NeckNeoplasms, Glandular and Epithelial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAkamis Bio Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAkamis Bio Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisSquamous Cell Carcinoma of Head and NeckNeoplasms, Glandular and Epithelial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A